CFDE Data Portal | Search LPAL2

	Label	Description
	LPAL2 associations Collection (Entity type)	Associations for LPAL2_associations
	LPAL2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	LPAL2 Gene (Entity type)	ENSG00000290613 - lipoprotein(a) like 2 (pseudogene)
	GSE199538 GSE199539 enzalutamide 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE244730 erlotinib PC-9 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE103567 EZH2 inhibition 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212057 SIRT6 overexpression 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE156761 dopamine neuron 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

LPAL2 associations

Associations for LPAL2_associations

LPAL2 associations.tsv

A file from IDG as part of the Harmonizome project

LPAL2

ENSG00000290613 - lipoprotein(a) like 2 (pseudogene)

GSE199538 GSE199539 enzalutamide 2 v 1 human dn

A Gene Set from LINCS

GSE176008 pyridoxine 7 v 3 human dn

A Gene Set from LINCS

GSE244730 erlotinib PC-9 0 v 1 human up

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 4 v 7 human dn

A Gene Set from LINCS

GSE103567 EZH2 inhibition 5 v 2 human dn

A Gene Set from LINCS

GSE212057 SIRT6 overexpression 3 v 7 human dn

A Gene Set from LINCS

GSE156761 dopamine neuron 0 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.